COX10

COX10 is a critical mitochondrial enzyme responsible for heme a biosynthesis, an essential component for the proper assembly and function of cytochrome c oxidase (Complex IV) in the electron transport chain. 

Mutations in COX10 can disrupt oxidative phosphorylation, leading to severe mitochondrial disorders such as Leigh syndrome, cytochrome c oxidase deficiency, and multi-system energy metabolism impairments.

What is COX10?

Cytochrome c oxidase assembly protein 10 (COX10) is a mitochondrial protein involved in cellular energy production. 

Its primary role is to help build cytochrome c oxidase (COX), also called complex IV, a key component of the electron transport chain (ETC). This chain drives oxidative phosphorylation, which generates most of the cell's ATP. 

COX10 Gene and Protein

COX10 is a nuclear gene that encodes a mitochondrial farnesyltransferase enzyme critical for heme a biosynthesis. Specifically, the COX10 enzyme converts heme B into heme O—an essential early step before COX15 further modifies heme O into heme a. 

Heme a is a vital prosthetic group required for the proper assembly and function of cytochrome c oxidase (Complex IV), the terminal enzyme of the electron transport chain that drives ATP production. 

Mutations in COX10 disrupt this biosynthetic process, leading to impaired COX assembly and reduced energy production. Such dysfunction underlies severe mitochondrial disorders, including Leigh syndrome, leukodystrophy, tubulopathy, and cardiomyopathy. 

Functional assays in yeast demonstrate that while some COX10 variants retain partial activity, loss-of-function mutations result in negligible COX activity.

COX10 Mutations

The following clinical scenarios can occur due to mutations in the COX10 gene:

Leigh Syndrome

Leigh syndrome is a severe, early-onset neurodegenerative disorder caused by mitochondrial dysfunction, leading to progressive loss of motor and cognitive skills, respiratory failure, and early death, often in infancy. 

It is genetically heterogeneous, with various mutations in several genes able to affect different mitochondrial respiratory chain complexes. One such mutation is in the COX10 gene, which disrupts cytochrome c oxidase (Complex IV), an essential enzyme for oxidative phosphorylation. 

COX10 deficiency impairs ATP production, leading to widespread neurological damage, particularly in high-energy-demand tissues like the brainstem and basal ganglia. Patients with COX10 mutations often present with progressive encephalopathy, seizures, and respiratory complications. 

Despite advancements in genetic understanding, treatment remains largely supportive, with research ongoing into targeted mitochondrial therapies.

Cytochrome C Oxidase Deficiency

COX10 mutations disrupt cytochrome c oxidase (Complex IV) function, impairing mitochondrial energy production and leading to a spectrum of conditions.

While some mutations cause Leigh syndrome, a severe neurodegenerative disorder, others result in milder mitochondrial dysfunction, presenting as neuromuscular weakness, metabolic abnormalities, or multi-organ involvement without Leigh syndrome. 

Symptoms range from hypotonia, myopathy, and lactic acidosis to cardiac and hepatic dysfunction, with severity influenced by residual COX activity. Rare cases of adult survival with nonfunctional COX10 alleles suggest compensatory genetic mechanisms. 

Genetic testing is essential for diagnosis, and while treatment is mainly supportive, ongoing research explores mitochondrial-targeted therapies.

Who Should Get COX10 Genetic Testing?

Genetic testing for COX10 mutations is recommended in the following scenarios:

Clinical Features Suggestive of Leigh Syndrome or Similar Encephalomyopathies

Patients with progressive neurological decline, characteristic MRI findings, and lactic acidosis should be evaluated for COX10 mutations.

Biochemical Evidence of COX Deficiency

If muscle or skin fibroblast enzyme assays show reduced COX activity, COX10 testing can help confirm the underlying genetic cause.

Family Members of Individuals with Known COX10 Mutations

In autosomal recessive conditions, each parent is typically a carrier; siblings may be at risk of inheriting pathogenic variants. Carrier or predictive testing allows families to understand reproductive risks and plan accordingly.

Prenatal Testing (Selected Cases)

Couples with a known history of severe COX10-related disorders may choose prenatal testing to assess the risk to a developing fetus.

Genetic counseling is essential to accompany the testing process to guide families through the results, their implications, and potential reproductive decisions.

Test Procedure and Interpretation

The following section outlines the testing procedures and interpretation.

Testing Procedure and Preparation

Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for COX10 genetic testing are considered to be without mutations that can alter the activity of the COX10 proteins.

Clinical Implications of Positive COX10 Mutations

The clinical implications of a positive COX10 mutation test result will vary by individual, although COX10 mutations in symptomatic patients may signal a need for further assessment and possibly treatment, especially in the setting of neurological symptoms.

Patients or practitioners with questions about the clinical implications of COX10 mutations should seek further assessment with a genetic counselor or expert. 

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.